Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05891769 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Study acronym: 18FCH
StatusRecruiting
PhasePhase 2/3
Started2023-09-27
View on ClinicalTrials.gov ↗
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Amendment record

Amended 3 times since 2023-05-26; most recent filed 2026-06-19. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-06-19
Amendment Study Status, Oversight v3
2025-09-03
Amendment Study Status, Oversight v2
2024-04-15
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2023-05-26
Original filing
Trial Details
NCT Number NCT05891769
Lead Sponsor Andrei Iagaru
Conditions Parathyroid Adenoma
Enrollment 100 participants
Start Date 2023-09-27
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-24